If you know someone battling depression or Alzheimer’s, Dr. Herriot Tabuteau might just become your new hero. For years, millions of patients suffering from these devastating conditions have struggled ...

Oral triptans are considered the industry gold standard acute treatments and there are currently seven approved, all with ...

Axsome Therapeutics, Inc.’s AXSM share price has dipped by 8.23%, which has investors questioning if this is right time to ...

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...

Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo Axsome did not address a regulatory filing timeline for Sunosi in the indication. CEO Herriot Tabuteau, M.D., said that ...

Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions in multiple Phase 3 trials. The FDA has greenlit Axsome to submit an sNDA ...

FDA approves Symbravo for acute treatment of migraine in adults Feb 6, 2025 Guideline on migraine prevention says no clinically important advantages for newer, expensive medications ...

Across 3 clinical trials, atogepant vs placebo was associated with reduced weekly and monthly migraine days by week 4. Atogepant, an oral calcitonin gene-related peptide receptor antagonist ...

In January 2025, the FDA approved Axsome’s Symbravo (meloxicam and rizatriptan) or AXS-07 for the acute treatment of migraine with or without aura in adults. The company expects to launch ...